Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

SiteOne Therapeutics

Request full access

Developing novel therapeutics focused on the peripheral nervous system,

San Francisco, United StatesFounded 2010Biotech & Life Sciences

About SiteOne Therapeutics

SiteOne Therapeutics, Inc. is a biopharmaceutical firm established in 2011, focusing on the development of non-opioid pain relief medications. The company was co-founded by George Miljanich and John Hunter, who both possess extensive experience in the field of neuroscience and ion channel modulation from their time at Elan Pharmaceuticals. Their work is rooted in over three decades of research into the biology and structure of the Nav1.7 sodium ion channel, a genetically validated target for pain signals.

The company's primary business involves discovering and advancing a new class of highly selective sodium ion channel (Nav) inhibitors. By targeting Nav1.7, SiteOne aims to stop the transmission of pain signals at their source without the central nervous system side effects and addictive potential associated with opioids. This positions the company within the specialty pharmaceutical market, specifically addressing the significant unmet need for safer and more effective analgesics for conditions like acute, chronic, and neuropathic pain. The business model is typical of a clinical-stage biopharmaceutical company, revolving around research and development, securing intellectual property, and progressing drug candidates through the FDA's clinical trial phases, with revenue generation likely tied to partnerships, licensing deals, or eventual commercialization of an approved drug.

SiteOne's lead product candidates are ST-2427 and ST-2645, which are being investigated for treating moderate-to-severe pain. ST-2427, an oral medication, has successfully completed Phase 1 clinical trials, demonstrating a favorable safety and tolerability profile. The development of these candidates is supported by a robust intellectual property portfolio. A significant milestone was achieved in 2024 when the company secured an oversubscribed $45 million Series D financing round, co-led by Braidwell LP and existing investor TPG's The Rise Fund. This funding is intended to advance ST-2427 through Phase 2 clinical trials for multiple pain indications.

Source: Dealroom company data

At a glance

Status
Acquired
Employees
3
Open positions
None listed
Dealroom signal
28.3/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Verified Unicorns and $1B Exits, Biotech and Pharma, DT and LS, science-based
Technology
Deep Tech
Business model
Marketplace & ecommerce
Client focus
B2C

Funding history

6 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
ACQUISITIONOther financing May 2025 $1B $1B Eli Lilly ↗
SERIES COther financing Dec 2024 $100M $400M OrbiMed · Mission BioCapital · BSQUARED Capital · Wellington Management ↗
Showing the latest 2 of 6 recorded eventsBook a demo for the full funding history →

Growth signals

SiteOne Therapeutics website traffic

Latest recorded traffic for SiteOne Therapeutics is 0 monthly website visits. SiteOne Therapeutics's team declined 25% over the past year.

Latest monthly visits0 1-year team growth-25%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

SiteOne Therapeutics in the San Francisco ecosystem

Live from Dealroom

The SiteOne Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

12 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A6 investors entered at this stage

  • Sears Capital Management
  • Bay Capital
  • BioBrit
  • Mission Bay Capital
  • NEXT Frontier Capital
  • Amgen

Series B and later5 investors entered at this stage

Other known investors1 additional known investor

  • Eli Lilly
Team profiled 4 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇺🇸 United States100%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about SiteOne Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See SiteOne Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.